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Abstract
Signal transduction and cell responses after stimulation with heregulin b-1 (HRG) are examined in HCC2998 and MKN45-1
cells, which have been used for a model system to study the formation of signet ring carcinomas, one of poorly
differentiated adenocarcinomas. HRG stimulation causes rounding of the cells, responding to HRG. The adherens junction,
which is present in the control cells, is disrupted and cell-cell interaction is lost after stimulation. Inhibition of
phosphatidylinositol (PI)-3 kinase or p38 MAP kinase blocked this reaction, which indicates that the PI-3 kinase-p38 MAP
kinase pathway is required for this reaction. Inhibition of the p38 MAP kinase pathway resulted in immediate restoration of
cell-cell interaction. This result indicates that signaling for adherent molecules is strictly regulated by growth factor
signaling. Expression of MUC1 at the cell surface is also observed and found to be expressed only after HRG stimulation. The
total amount of MUC1 remains unchanged, suggesting that this amount is not due to induction of gene expression but to
translocation of MUC1 from the inner membrane to the plasma membrane. This reaction is independent of the cytohesin
pathway but dependent on PI-3 kinase activity. In addition to these reactions, HRG stimulates cell growth of both HCC2998
and MKN45-1 cells, depending on the ERK pathway given that the MEK inhibitor abolishes this effect. Therefore, HRG
induces various reactions in HCC2998 and MKN45-1 cells by different pathways. These reactions are all related to
characteristics of tumors, which implicates that HRG signaling can contribute to the formation of tumors.
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Introduction
Heregulins/neuregulins are growth factors that form a family
and present at the apical side of the epithelial cells: their signaling
has been implicated to influence cell polarity [1–5]. HRG takes
ErbB3/HER3 as a receptor [6]. ErbB3 is a member of the EGF
tyrosine kinase receptor family but may have lost its enzymatic
activity because of a substitution of the amino acid essential for the
process [7–9]. HRG activates ErbB3 to make heterodimers with
other members of the EGF receptor family. The major signaling
pathways that are activated after HRG stimulation are suggested
to be the phosphatidylinositol (PI) 3-kinase and the ERK pathways
[8,10]. Activation of ErbB3 by making a heterodimer with ErbB2
has been suggested to be related to formation of breast cancers
[6,10–14].
Signet ring cell carcinomas are one of the poorly differentiated
adenocarcinomas originally found mainly in northeastern Asia as
stomach cancers. However, nowadays this kind of cancer is
found in various areas and in various organs [15,16]. Because
these cells grow without interaction with other cells and because
cells secrete mucins, such as MUC1, to cover the cells, chemical
treatment of these carcinomas and related surgery are extremely
difficult.
In many of the signet ring cell carcinoma cell lines, the ErbB2/
ErbB3 pathway is often constitutively activated by the autocrine
loop of ErbB2-ErbB3-Muc4-ErbB2[17,18,19]. No further activa-
tion of the ErbB2/ErbB3 pathway even if cells are stimulated by
HRG. But in the other cell lines, no activation of ErbB2/ErbB3 is
observed. As shown in Table 1, it appears that there are two types
of signet ring carcinomas: ErbB2/ERbB3 activated and non-
activated [20–22]. HCC2998 cells are the highly differentiated
colon adenocarcinoma cells used as model cells in studies of the
formation of signet ring carcinomas [23]. When constitutively
activated PI-3 kinase is expressed in the cells, cell-cell contact is
lost and secretion or cell surface expression of mucins is enhanced
to become very similar to that of signet ring carcinoma cells
[17,23]. To show the effect of HRG is not limited to HCC2998
cells, a gastric adenocarcinoma line MKN45-1 was also used. This
cell line derives from MKN45 poorly differentiated adenocarci-
mona line [24]. While we were culturing these cells, relatively flat
cells appeared. This was unusual because poorly differentiated
adenocarcinoma cells rarely yield highly differentiated adenocar-
cinoma cells [23].We cloned these cells and named them MKN45-
1. These cells behaved similarly to HCC2998 cells, have been used
as a model for signet ring cell carcinomas [23]. However, the
regulation of these cell responses is not well understood.
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p38 MAP kinase, which lies downstream of the PI-3 kinase in these
cells, is known [18]. In addition, these results were obtained only
in tumor cell lines or after expression of a constitutively active
mutant. Therefore, the effect of stimulation with the natural ligand
on intact cells should be examined precisely.
In this paper, we demonstrate that HRG can cause loss of cell-
cell contact and enhance the secretion of MUC1, a mucin, in
HCC2998 and MKN45-1 cells, as well as cause cell growth
through different signaling pathways.
Materials and Methods
Cells and culture conditions
HCC2998 and MKN45-1 cells were cultured in RPMI1640
medium supplemented with 5% fetal calf serum [23]. In the
experiments cells were stimulated with HRG (100 ng/ml), which
was purchased from R&D Systems (Minneapolis, MI). HRG was
given to the cells every 24 h because its effects last only about that
long.
Antibodies and reagents used in this study
Anti-ErbB3 (C-17) and anti-p38 antibodies were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Anti-
ErbB2 antibody, CB11, was from Biocare Medicals (Concord,
CA). Anti-MUC1 antibodies were from Acris Antibodies GmbH
(Herford, Germany) and Millipore (Billerica, MA). Anti-E-
cadherin and b-catenin antibodies were from GE Healthcare
(London, UK). Anti-ERK, Anti-phosho-ERK, anti-p38 MAP
kinase, anti-phospho-p38 MAP kinase, and anti-phospho-ErbB3
antibodies were from Cell Signaling Technology (Danvers, MA).
A potent PI-3 kinase inhibitor, ZSTK474 [25] was a kind gift
from Dr. S. Yaguchi (Zenyaku Kogyo Co. Ltd). A MEK inhibitor,
PD98059, and a p38 MAP kinase inhibitor, SB202190, were
purchased from WAKO Co. Ltd. (Tokyo). We used SB203580 9
(WAKO Co. Ltd.) as a p38 MAP kinase inhibitor. However, the
results were always the same as those with SB202190. We
therefore present the results of SB202190 in this paper. SecinH3
was from Millipore (Billerica, MA).
Immunocytochemistry
Cells were fixed with 3.7% formaldehyde. After treatment with
PBS with or without 0.2% Triton X100, cells were incubated with
primary antibodies for 1 h and visualized with Alexa488 or
Alexa594-conjugated second antibodies (GE Healthcare). F-actin
was visualized by TRITC-phalloidin (Sigma-Aldrich, St. Louis,
MO). Cells were observed by confocal microscopy (Olympus,
FV300).
Western blotting, immunoprecipitation, and
biotinylation of the cells
Western blotting was done using PVDF membrane as described
before [26]. Immunoprecipitation and biotinylation of the cells
were done as described before [19].
Fractionation of the cells
Cells were suspended in a buffer containing 10 mM Tris-HCl,
pH 7.5, 10 mM NaCl, and a proteinase inhibitor cocktail; they
were then homogenized in a Dounce homogenizer. After
removing the nuclei by low-speed centrifugation, the cytoplasmic
fraction was further fractionated into the membrane and the
cytosolic fractions by spinning at 45,000 rpm for 60 min.
Examination of cell growth
1610
5 cells were plated in 3.5 cm dishes. Cells were harvested
by trypsinization and counted every day.
Flow cytometry
After fixation with 3.7% formaldehyde, cells were scraped and
passed though a syringe to break cell aggregates. After treatment
with anti-MUC1 antibody, cells were washed with PBS once and
reacted with an Alexa488-conjugated second antibody (GE
Table 1. Characteristics of signet ring cell carcinoma cell
lines
a.
Cell lines Status of ErbB2/ErbB3 complex, response to HRG
HSC39 activated (phosphorylated), no further activation
HSC45 not detected, no reaction
HSC58 activated (phosphorylated), no further activation
HSC60 not detected, no reaction
NUGC4 activated (phosphorylated), no further activation
KATOIII activated (phosphorylated), no further activation
aStatus of ErbB2 and ErbB3; and responses to HRG are shown in various signet
ring cell carcinoma cell lines. HSC45, HSC58, and HSC60 grow as mixtures with
other types of cells and cannot be purified.
doi:10.1371/journal.pone.0029599.t001
Figure 1. Reaction of HCC2998 cells to HRG stimulation. (A)
HCC2998 cells were treated with HRG (100 ng/ml) for the indicated
time. Cells were observed under the microscope. ‘‘,16 h SB’’ indicates
addition of SB202190 (1 mM) to the culture after incubation with HRG
for 16 h. (B) HCC2998 cells were treated with HRG (100 ng/ml) for the
indicated time. Protein levels and their phosphorylation were analyzed
by Western blotting. (C) HCC2998 cells were treated with HRG in the
presence of PD98059 (PD), SB202190 (SB), or ZSTK474 (ZSTK) for 24 h.
Cells were observed under the microscope.
doi:10.1371/journal.pone.0029599.g001
Heregulin Stimulation of HCC2998 and MKN45-1 Cells
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e29599Healthcare). After washing with PBS three times, the samples were
subjected to flow cytometry.
Results
HCC2998 cells express ErbB2 and ErbB3, and respond to
HRG
HCC2998 cellsweretreated withHRG.AsshowninFig.1A,loss
of cell-cell contact was observed starting from a few hours after
HRG stimulation. Because cells do not move much, it was hard to
tell whether they really dissociated; but rounding of the cells
suggested that they may have lost cell-cell contact. Regardless,
change of cell shape suggests that these cells responded to HRG.
These results were further confirmed using another cell line,
MKN45-1 (Fig. 2A). These cells moved a little more than the
HCC2998 cells, so dissociation of the cells was obvious. Given these
results, the ErbB2/ErbB3 signaling pathway and its outputs were
examined. As shown in Fig. 1B, in HCC2998 cells both ErbB2 and
Figure 2. Reaction of MKN45-1 cells to HRG stimulation. (A)
MKN45-1 cells were treated with HRG (100 ng/ml) for the indicated
time. Cells were observed under the microscope. (B) HCC2998 cells
were treated with HRG (100 ng/ml) for the indicated time. Protein levels
and their phosphorylation were analyzed by Western blotting. (C)
HCC2998 cells were treated with HRG in the presence of PD98059 (PD),
SB202190 (SB), or ZSTK474 (ZSTK) for 24 h. Cells were observed under
the microscope.
doi:10.1371/journal.pone.0029599.g002
Figure 3. E-cadherin and b-catenin in HCC2998 cells stimulated with HRG. (A) HCC2998 cells were stimulated with HRG for the indicated
time. E-cadherin or b-catenin was co-stained with F-actin. (B) HCC2998 cells were treated with HRG for 24 h. Cytoplasmic fraction of the cells was
further fractionated into the membrane and the cytosolic fractions. The membrane fraction was dissolved in the same volume of the sample buffer
used for electrophoresis of the cytosolic fraction. The resulting samples were analyzed for the levels of E-cadherin and b-catenin by Western blotting.
(C) Effect of inhibitors for various signaling molecules (PD98059, 10 mM; SB202190, 1 mM; ZSTK474, 1 mM) on HCC2998 cells treated with HRG for 24 h.
E-cadherin or b-catenin was co-stained with F-actin. ‘‘16h, SB’’ indicates addition of SB202190 (1 mM) to the culture after incubation with HRG for
16 h and further incubation for 8 h. Sections at about the center of the cells are shown. (D) Cells were treated with HRG for 22 h. Then 1 mM
SB202190 was added for the indicated time. Cell morphology and localization of E-cadherin was monitored by immunostaining. Sections of the cells
at about the middle parts are shown.
doi:10.1371/journal.pone.0029599.g003
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detectable 15 min after stimulation with HRG and continued for at
least 24 h. Phosphorylation of ErbB3 was also detectable for at least
24 h in MKN45-1 cells (Fig. 2B). Degradation of ErbB3 was
observed in both cell lines after incubation with HRG for 24 h,
although phosphorylation of ErbB3 was still detectable, suggesting
that, once phosphorylated on tyrosine, some ErbB3 may be
degraded. Prolonged activation of ErbB3 may also lessen the level
of intact ErbB3. Phosphorylation of ErbB3 has been shown to
activate the ERK pathway and the PI-3 kinase pathway, which has
beensuggested to activate p38 MAP kinase in these cells [18]. Upon
activation of ErbB3, tyrosin phosphorylation of ERK and p38 MAP
kinase was detected. Unlike the case when the cells are stimulated
with other growth factors, these kinases were activated for a long
period. This may be due to prolonged activation of ErbB3.
HRG induces dissociation of the cells
Since expression of dominant-active PI-3 kinase or MKK6 has
been shown to induce rounding of the cells, the effect of inhibitors
on the pathway that contains these enzymes was tested. As shown
in Fig. 1C and 2C, a PI-3 kinase inhibitor, ZSTK474, and a p38
MAP kinase inhibitor, SB202190, blocked the dissociation of the
cells; but a MEK inhibitor, PD98059, failed to do so.
Dissociation of the cells led us to examine the behavior of E-
cadherin and b-catenin. In control cells, signals of E-cadherin were
readily detectable at the cell-cell contact (Fig. 3A and 4A). F-actin
was also accumulated at the cell-cell contact to co-localize with E-
cadherin. After incubation of the cells with HRG for 2 h, some of
the cells dispersed, and E-cadherin and b-catenin at the peripheral
region became slightly fuzzy, suggesting that breakdown of the
adherens junctions had already started. These proteins gradually
diffused towardinside the cells and finally became even at 24 h after
HRG stimulation. F-actin was often left at the peripheral region of
HCC2998 cells even after cells were dispersed. In MKN45-1 cells,
diffuse distribution of F-actin was seen earlier than in HCC2998
cells. The reason F-actin behaved differently in these cells is not
known. During this procedure, expression levels of E-cadherin, a-
catenin, and b-catenin remained unchanged (Fig. 1B and 2B).
Movement of the proteins was also monitored by a biochemical
method in HCC2998 cells. Cytoplasmicfractionwas fractionated, and
distribution of E-cadherin and b-catenin was examined. As shown in
Fig. 2B, E-cadherin remained in the membrane fraction, suggesting
that it remains on the inner membrane even if internalized. However,
a considerable amount of b-catenin moved to the cytosol, suggesting
that b-catenin was released from the adherens complex, which
consisted of E-cadherin and three types of catenins. These results
suggest that the complex can be broken down after internalization.
Behavior of E-cadherin, b-catenin and F-actin in the cells
cultured in the presence of PI-3 kinase, MEK, and p38 MAP
kinase inhibitors was examined (Fig. 3C and 4A). In both cell lines,
inhibition of the PI-3 kinase or the p38 MAP kinase blocked
dissociation of the cells and kept the structure of E-cadherin, b-
catenin, and F-actin intact even after treatment with HRG,
suggesting that the PI-3 kinase-p38 MAP kinase pathway regulated
the adherens junction. PD98059 was not effective in doing so. It is
interesting to note that even if cell-cell contact was lost by
treatment with HRG for 16 h, the cell-cell contact was restored
within 8 h by addition of SB202190 even in the presence of HRG
(Figs. 1A and 3C). These results suggest that adherens junctions
are regulated reversibly. Reaction of the cells just after SB202190
treatment was examined precisely.
E-cadherin was diffusely distributed by treatment of the cells
with HRG for 22 h, which moved to the plasma membrane
leaving almost no signal in the cytosol within 5 min accompanied
by rounding of the cells. In the case of MKN45-1 cells, they
immediately started to bind to the dish and within 15 min cytosol
became turbid again. The reaction of the cells to the signaling of
the p38 MAP kinase pathway was quite fast (Fig. 3D and 4B).
However, how long it takes to make cell-cell contact is not known.
HRG treatment of HCC2998 cells induces expression of
MUC1 at the cell surface
Because enhancement of mucin secretion has been observed in
signet ring carcinoma cells, behavior of MUC1, one of the mucins,
has been examined. When cells were stained with anti-MUC1
Figure 4. E-cadherin and b-catenin in MKN45-1 cells stimulated
with HRG. (A) MKN45-1 cells were stimulated with HRG for the
indicated time. E-cadherin or b-catenin was co-stained with F-actin.
Effect of inhibitors for various signaling molecules (PD98059, 10 mM;
SB202190, 1 mM; ZSTK474, 1 mM) on MKN45-1 cells treated with HRG for
24 h. (B) Cells were treated with HRG for 22 h. Then 1 mM SB202190 was
added for the indicated time. Cell morphology and localization of E-
cadherin were monitored by immunostaining. Sections of the cells at
about the middle parts are shown.
doi:10.1371/journal.pone.0029599.g004
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time. A second dose of HRG was given after incubation for 24 h for the 2-day cultures. Muc1, with or without permeabilization, was stained with anti-
MUC1 antibody. On the right sides, Nomarski view of the same cells are shown. (B) HCC2998 cells were stimulated with HRG for the indicated time.
Total MUC1 levels and MUC1 at the cell surface (biotinylation) were analyzed by Western blotting. Detecting MUC1 expressed at the cell surface
required 50 times more protein than was used for simple Western blotting. (C) Effect of inhibitors for various signaling molecules on MUC1
expression at the cell surface was examined. HCC2998 cells were cultured for 2 days in the presence of HRG. (D) HCC2998 cells bearing inducible
genes for dominant active PI-3 kinase (BD110) and MKK6 were used [18,23]. They were infected with adenovirus bearing Cre recombinase to induce
the gene. Adenovirus bearing LacZ was used as a control. (E) Experiments similar to C were done using SecinH3 (20 mg/ml).
doi:10.1371/journal.pone.0029599.g005
Figure 6. Expression of MUC1 at the cell surface after
stimulation with HRG. (A) MKN45-1 cells were stimulated with
HRG for the indicated time. A second dose of HRG was given after
incubation for 24 h for the 2-day cultures. Muc1, with or without
permeabilization, was stained with anti-MUC1 antibody. On the right
sides, Nomarski views of the same cells are shown. (B) Effect of
inhibitors for various signaling molecules on MUC1 expression at the
cell surface was examined. MKN45-1 cells were cultured for 2 days in
the presence of HRG.
doi:10.1371/journal.pone.0029599.g006
Figure 7. Flow cytometry of HCC2998 and MKN45-1 cells.
HCC2998 and MKN45-1 cells treated with or without HRG for 2 days. A
second dose of HRG was given 24 h after the first dose. Cells were fixed,
dispersed, and stained with an anti-MUC1 antibody, followed by the
second antibody conjugated with Alexa488. The resulting cells were
subjected to flow cytometry.
doi:10.1371/journal.pone.0029599.g007
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suggesting that MUC1 was not expressed at the cell surface
(Fig. 5A and 6A). MUC1 was present inside the cells because it was
detected after permeabilization (Fig. 5A). This was confirmed by
Western blotting (Fig 5B). After treatment of the cells with HRG
for 1 day, presence of MUC1 at the cell surface became visible
(Fig. 5A). Biotinylation of the protein at the cell surface followed by
precipitation with avidin-beads in combination with Western
blotting supported this idea (Fig. 5B). This was further confirmed
by flow cytometry (Fig. 7). In non-stimulated HCC2998 and
MKN45-1 cells very low level of signals were detected. In contrast,
after two days of stimulation of the cells with HRG, significant
levels of the signals were detected, suggesting that MUC1 is
expressed at the cell surface. The total MUC1 level remained
constant during two days of HRG treatment (Fig. 5B). This
reaction was inhibited by ZSTK474 but not by SB202190 (Fig. 5C
and 6B). Expression of a constitutively activated PI-3 kinase,
BD110 [23], induced expression of MUC1 at the cell surface; but
that of activated MKK6 failed to do so (Fig. 5D). These results
suggest that translocation of MUC1 is dependent on PI-3 kinase
activity but also that the signaling pathway is distinct from that for
regulation of adherens junction.
Tosee the involvementof cytohesinsinthe translocation of Muc1,
the effectofSecinH3, a cytohesin inhibitor,was examined.Asshown
inFig. 5E,SecinH3did not inhibittranslocation ofMuc1, suggesting
that cytohesins were not involved in translocation of Muc1.
The ERK pathway may be important for cell growth
The effect of HRG on cell growth was examined. HRG
stimulation of HCC2998 and MKN45-1 cells enhanced cell
growth (Fig. 8). This was slightly inhibited by inhibition of the PI-3
kinase or p38 MAP kinase in HCC2998 cells but not in MKN45-1
cells. In contrast, inhibition of MEK severely inhibited cell growth.
Even in the presence of HRG, the growth rate was lower than the
control cells. Because inhibition of MEK decreased growth of
control cells as well, it is likely that MEK contributes to cell growth
in HCC2998 and MKN45-1 cells and that complete inhibition of
MEK results in a very low growth rate (Fig. 8). Super activation of
MEK by HRG stimulation may enhance the cell growth greatly.
Discussion
As demonstrated in this paper, HRG induces various cell
responses. It is interesting that each signaling pathway activated by
HRG stimulation correlates with different cell responses (Fig. 9).
For instance, p38 MAP kinase is likely to be involved only in cell-
cell dissociation and not in cell growth or translocation of MUC1.
On the other hand MEK was not involved in cell-cell dissociation
or translocation of MUC1. The PI-3 kinase pathway may branch
into at least two pathways: one for regulation of cell-cell contact
through p38 MAP kinase, the other for translocation of mucins.
Therefore, each pathway is likely to have an independent role.
Downstream signaling of MEK remains to be studied.
How tight and adherens junctions are formed has been widely
studied [27–33]. However, how these junctions are regulated has
not yet received much attention. These junctions must be
regulated in some way because they are disrupted in cases such
as cell division. Therefore, some systems must regulate these
junctions. The p38 MAP kinase cascade might be one of them.
Dissociation of the cells by activation of the p38 MAP kinase
cascade takes several hours. However, movement of E-cadherin
Figure 8. Effect of inhibitors for signaling molecules on growth of HCC2998 and MKN45-1 cells. (A and B) HCC2998 cells were plated in
3.5 cm dishes at a cell density of 1610
4 and stimulated with HRG every day in the presence or absence of drugs. Cells in the dishes were counted.
(C and D) Similar experiments were done with MKN45-1 cells. Experiments were done three times and plotted on the graph. The standard deviations
for each point were less than 4%. Control: without HRG treatment.
doi:10.1371/journal.pone.0029599.g008
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p38 MAP kinase pathway was very quick. Therefore, the p38
MAP kinase pathway could directly modulate the adherent
molecules. The fact that the p38 MAP kinase was activated for
at least 24 h after HRG treatment to induce scattering supports
this idea.
Cytohesins are PI-3 kinase dependent factors for transportation
of proteins. Translocation of MUC1 is suggested to be
independent of this factor because SecinH3, a cytohesin inhibitor,
did not block the translocation. The fact that overexpression of
ARNO or an ARNO mutant incapable of binding to phospha-
tidylinositol trisphosphate did not alter the translocation supports
this idea (data not shown). Therefore, there must be a cytohesin
independent pathway that carries out translocation of MUC1. In
signet ring cell carcinoma cells, cells are always covered by mucins
without any stimulation. It is likely that switch of this unknown
pathway for translocation of mucins to the plasma membrane is
constitutively on because of constitutive activation of the ErbB2/
ErbB3 pathway.
The cell responses mentioned above are all related to malignant
transformation of the cells. Therefore, it is conceivable that the
ErbB2/ErbB3 pathway can contribute to formation of malignant
tumors. Indeed, ErbB2 has been identified as an oncogene [34],
and anti-ErbB2 antibody has been used as an anti-tumor drug
[35,36], although ErbB3 is not identified as an oncogene because
it may lack enzyme activity. How HRG contributes to the
activation of the ErbB2/ErbB3 pathway in vivo is not well
understood. Further study may be required to grasp the whole
picture of ErbB2/ErbB3-dependent tumors.
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